A multiplex platform for the identification of ovarian cancer biomarkers
| Autor: | Kristin L. M. Boylan, Kate Geschwind, Joseph S. Koopmeiners, Melissa A. Geller, Timothy K. Starr, Amy P. N. Skubitz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Clinical Proteomics, Vol 14, Iss 1, Pp 1-21 (2017) |
| Druh dokumentu: | article |
| ISSN: | 1542-6416 1559-0275 |
| DOI: | 10.1186/s12014-017-9169-6 |
| Popis: | Abstract Background Currently, there are no FDA approved screening tools for detecting early stage ovarian cancer in the general population. Development of a biomarker-based assay for early detection would significantly improve the survival of ovarian cancer patients. Methods We used a multiplex approach to identify protein biomarkers for detecting early stage ovarian cancer. This new technology (Proseek® Multiplex Oncology Plates) can simultaneously measure the expression of 92 proteins in serum based on a proximity extension assay. We analyzed serum samples from 81 women representing healthy, benign pathology, early, and advanced stage serous ovarian cancer patients. Results Principle component analysis and unsupervised hierarchical clustering separated patients into cancer versus non-cancer subgroups. Data from the Proseek® plate for CA125 levels exhibited a strong correlation with current clinical assays for CA125 (correlation coefficient of 0.89, 95% CI 0.83, 0.93). CA125 and HE4 were present at very low levels in healthy controls and benign cases, while higher levels were found in early stage cases, with highest levels found in the advanced stage cases. Overall, significant trends were observed for 38 of the 92 proteins (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|